OncoPharm

A primer on primary endpoints used in oncology clinical trials. Tailored for those new to in-depth evaluations of oncology literature.

Topics on this week's Pod include: -Lurbinectedin in SCLC -Nivolumab is esophageal cancer -Pembrolizumab for TMB-high cancers -Gemtuzumab ozogamicin for pediatric AML -Venetoclax + HMA for adult (unfit) AML -Gardasil for prevention of SCCHN -Perhaps the biggest non-oncopharm news of the year?

LD Vs Ld by John Bossaer

Recapping lots of updates from ASCO 2020. Then (20:00) we chat with Shannon Hough, oncology pharmacy specialist, to talk about her ASCO abstract (https://meetinglibrary.asco.org/record/185996/abstract) on pharmacist interventions in managing CINV.

Another week, another two new approved indications in NSCLC. We cover Checkmate-9La (Nivo/Ipi + 2 cycles of chemo) and ALTA-1L (1st Line brigatinib in ALK-rearranged NSCLC). Finally, we cover an interesting case report highlighting the need to determine CNS penetration of kinase inhibitors. (Lots of ASCO talk *next* week!)

There are 2 new Immunotherapy (without chemo) options for untreated metastatic NSCLC. We try to make sense of this evolving landscape. Then, we run through the latest TKI, ripretinib. Finally, we discuss a new approval for Kaposi sarcoma and our obligatory PARP inhibitors update of the week.

We now have a RET inhibitor, selpercatinib. This new drug for NSCLC and thyroid cancer is discussed as well as RET in general as a target. Then, we cover olaparib's latest approval for use in conjunction WITH bevacizumab for maintenance in HRD ovarian cancer based on PAOLA-1 (19:30). Finally, we run through IMBrave 150 (atezolizumab + bevacizumab) which may establish a new standard of care in HCC (22:20) and briefly discuss olanzapine for cancer-associated N/V and Ivosidenib for IDH1-mutated cholangiocarcninoma. RET fusions: https://doi.org/10.1016/j.ctrv.2019.101911 PAOLA-1: https://www.nejm.org/doi/full/10.1056/NEJMoa1911361 IMbrave150: https://www.nejm.org/doi/full/10.1056/NEJMoa1915745 Olanzapine: https://jamanetwork.com/journals/jamaoncology/article-abstract/2765323 Ivosidenib in cholangiocarcinoma: https://doi.org/10.1016/S1470-2045(20)30157-1

The podcast dives into the groundbreaking FDA approval of daratumumab for subcutaneous use, showcasing its advantages over traditional IV administration. It also explores capmatinib, the first drug approved for MET exon 14 skipping mutations, and its role in treating targeted lung cancers. The discussion highlights the safety and efficacy of these innovative treatments, alongside essential patient monitoring and their potential integration into cancer care regimens.

Topics of discussion: Q 6 week pembrolizumab dosing schedule FDA approved Updates on possible PARP inhibitor use. Niraparib for ovarian maintenance. Olaparib in prostate cancer (5:28) The monarcHER study of abemaciclib in HER+ MBC (12:20) The GRIFFIN study of Dara+VRD in myeloma (17:00)

Five (5!) new #oncopharm products to discuss. First, sacituzumab govitecan. Then, (9:30) tucatinib. Finally, (18:40) mitomycin gel, pemitgatinib, and selumetinib.